Sunshine Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
SBFM$2.71-2.9%Stored close · as of Nov 6, 2026
Contents
Defined Terms
Unless the context requires otherwise, references to “Sunshine,” “the Company,” “we,” “us” or “our” in this Form 10-K refer to Sunshine Biopharma, Inc. and its subsidiaries. The following are definitions for terms or abbreviations used in this Form 10-K:
| Adva-27a | The laboratory designation of the Company’s chemotherapy small molecule under development |
|---|---|
| ASC | Accounting Standards Codification |
| ASU | Accounting Standards Update issued by FASB |
| CAD | Canadian Dollar |
| COSO | Committee of Sponsoring Organizations of the Treadway Commission |
| COVID-19 | Novel coronavirus disease of 2019 |
| DIN | Drug Identification Number, an eight-digit number issued by Health Canada authorizing the sale of a drug in Canada |
| EPS | Earnings per share |
| EUA | Emergency Use Authorization |
| FASB | Financial Accounting Standards Board |
| FDA | U.S. Food and Drug Administration |
| FDIC | Federal Deposit Insurance Corporation |
| FTC | Federal Trade Commission |
| G&A | General and administrative |
| GAAP | Generally Accepted Accounting Principles |
| GMP | Good Manufacturing Practice |
| GST | Goods and Services Tax (Canada) |
| Health Canada | The Canadian drug regulatory body |
| IND | Investigational New Drug |
| IT | Information Technology |
| LNP | Lipid Nano Particle |
| K1.1 mRNA | The laboratory designation of the Company’s mRNA based anticancer therapy under development |
| MD&A | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
| MERS-CoV | Middle East Respiratory Syndrome Coronavirus |
| Mpro | Coronavirus main protease |
| mRNA | Messenger ribonucleic acid |
| NDA | New Drug Application |
| NOC | A Notice of Compliance issued by Health Canada to a drug manufacturing facility |
| Nora Pharma | Nora Pharma Inc., a wholly-owned subsidiary of the Company acquired on October 20, 2022 |
| NPN | Natural Product Number, an eight-digit number issued by Health Canada authorizing the sale of a natural product or a supplement in Canada |
| OTC | Over-The-Counter |
| pCPA | pan-Canadian Pharmaceutical Alliance, an alliance of the provincial, territorial and federal governments that determines generic drugs pricing based on a percentage of the brand-name reference products |
| PCT | Patent Cooperation Treaty |
| PLpro | Coronavirus papain-like protease |
| QST | Quebec Sales Tax (Canada) |
| R&D | Research and Development |
| ROU | Right of Use |
| SARS Coronavirus | Severe Acute Respiratory Syndrome Coronavirus, the group of coronaviruses that includes SARS-CoV-2, MERS-CoV, and SARS-CoV |
| SARS-CoV | Severe Acute Respiratory Syndrome Coronavirus that first appeared in 2003 |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus 2, the virus that causes COVID-19 |
| SBFM-PL4 | Laboratory designation of the Company’s COVID-19 treatment under development |
| SEC | U.S. Securities and Exchange Commission |
| SOC | Security Operations Center |
| street name | Securities held in the name of a brokerage firm on behalf of a client |
| Sunshine Canada | Sunshine Biopharma Canada Inc., a wholly owned subsidiary of the Company |
| U.S. | United States of America |
| USD | U.S. Dollars. All applicable references in this report refer to US Dollars and not Canadian Dollars (CAD) unless otherwise specifically stated. |
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.